Marie France Fassotte

Author

Also Known As

M F Fassotte, M. F. FASSOTTE, M. Fassotte, M.-F. Fassotte, M.F. Fassotte, Marie France Fassotte, Marie-France Fassotte, Marie‐France Fassotte

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

University of Liège Centre Hospitalier Universitaire de Liège

About

Marie France Fassotte is an author at University of Liège specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	994
2	Immunology	4	4	513
3	Health Sciences	2	2	481
4	Cell Biology	1	1	472
5	Gastroenterology	1	1	16

Marie France Fassotte

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging Guy Jérusalem, Yves Béguin, Marie France Fassotte, Blood	1999	556
Direct stimulation of cytokines (IL-1β, TNF-α, IL-6, IL-2, IFN-γ and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation D De Groote, P.F. Zangerle, Y. Gevaert, Cytokine InflammationCytokineImmunologyImmune RegulationIsolated Pbmc Stimulation	1992	472
Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL) Guy Jérusalem, Yves Béguin, Fadi Najjar, Annals of Oncology Positron Emission TomographyLymphoid NeoplasiaOncologic ImagingMedical ImagingMedicine	2001	268
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease Guy Jérusalem, Yves Béguin, Marie France Fassotte, Annals of Oncology Positron Emission TomographyMedical ImagingDiagnosisPathologyEarly Detection	2002	213
Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Guy Jérusalem, Yves Béguin, Marie France Fassotte, PubMed	2001	206
Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. G. Jerusalem, Yves Béguin, Marie France Fassotte, PubMed	2000	204
Whole-body 18F-FDG PET for the evaluation of patients with Hodgkinʼs disease and non-Hodgkinʼs lymphoma Guy Jérusalem, V. Warland, Fadi Najjar, Nuclear Medicine Communications	1999	158
18F-FDG PET in children with lymphomas Gisèle Depas, Caroline De Barsy, Guy Jérusalem, European Journal of Nuclear Medicine and Molecular Imaging Lymphoid NeoplasiaHematologyVeterinary SciencePathology18F-fdg Pet	2004	116
Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies Marc André, Étienne Baudoux, Dominique Bron, Transfusion	2003	47
Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging Guy Jérusalem, Yves Béguin, Marie France Fassotte, Blood	1999	41

Page 1